Immutep Limited (IMMP) Nasdaq

  • Ecco la 60° Edizione del settimanale "Le opportunità di Borsa" dedicato ai consulenti finanziari ed esperti di borsa.

    Questa settimana abbiamo assistito a nuovi record assoluti in Europa e a Wall Street. Il tutto, dopo una ottava che ha visto il susseguirsi di riunioni di banche centrali. Lunedì la Bank of Japan (BoJ) ha alzato i tassi per la prima volta dal 2007, mettendo fine all’era del costo del denaro negativo e al controllo della curva dei rendimenti. Mercoledì la Federal Reserve (Fed) ha confermato i tassi nel range 5,25%-5,50%, mentre i “dots”, le proiezioni dei funzionari sul costo del denaro, indicano sempre tre tagli nel corso del 2024. Il Fomc ha anche discusso in merito ad un possibile rallentamento del ritmo di riduzione del portafoglio titoli. Ieri la Bank of England (BoE) ha lasciato i tassi di interesse invariati al 5,25%. Per continuare a leggere visita il link

puoi postare cortesemente un link che riporta quanto da te scritto?
Mini Oral session

11MO - Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors (ID 420)​

Session Name
Mini Oral 2 (ID 36)
Speakers
  • Margarita Majem (Barcelona, Spain)
Date
Fri, 31.03.2023
Time
08:15 - 09:15
Room
Auditorium 1
Duration
5 Minutes

European Lung Cancer Congress 2023​

 
Grazie. Non credo che 5 minuti si rifletteranno sulla quotazione,ma mai dire mai
 
puoi postare cortesemente un link che riporta quanto da te scritto?
  • Tutti gli abstract regolari accettati per la presentazione all'ELCC 2023 come Proffered Paper (suffisso O), Mini Oral (suffisso MO), Poster (suffisso P o TiP) saranno pubblicati online tramite il sito web dell'ESMO alle 00:05 CET di giovedì 23 marzo 2023
  • Tutti gli abstract Late-breaking accettati per la presentazione all'ELCC 2023 come Proffered Paper o Mini Oral (prefisso LBA) saranno pubblicati online tramite il sito web dell'ESMO alle 00:05 CEST di martedì 28 marzo 2023
 
  • Tutti gli abstract regolari accettati per la presentazione all'ELCC 2023 come Proffered Paper (suffisso O), Mini Oral (suffisso MO), Poster (suffisso P o TiP) saranno pubblicati online tramite il sito web dell'ESMO alle 00:05 CET di giovedì 23 marzo 2023
  • Tutti gli abstract Late-breaking accettati per la presentazione all'ELCC 2023 come Proffered Paper o Mini Oral (prefisso LBA) saranno pubblicati online tramite il sito web dell'ESMO alle 00:05 CEST di martedì 28 marzo 2023
Grazie
 
Anch'io le ho a PMC 2,01 ma mi sto demoralizzando vederla scendere continuamente anche quando il resto biotech sale.
Sarei grato sentire un commento aggiornato di Grecale l'unico che solleva il morale con le sue lucide analisi. Grazie
 

11MO - Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors (ID 420)​

Speakers
  • Margarita Majem Tarruella (Barcelona, Spain)
Duration
5 Minutes

Background​

Eftilagimod alpha (E), a soluble LAG-3 protein, acts as an MHC class II agonist triggering activation of antigen-presenting cells (APC) and CD8 T-cells. Stimulating APCs and subsequent T cell recruitment with efti may revert PD-1/PD-L1 resistance. We report updated results from Part B of the TACTI-002 trial: 2nd line PD-1/PD-L1-resistant non-small cell lung carcinoma (NSCLC) patients (pts) treated with efti plus pembrolizumab (P).

Methods​

Pts with metastatic NSCLC unselected for PD-L1 expression and with resistance to 1st line PD-1/PD-L1 inhibitor-based therapy were enrolled. Primary endpoint (EP) was objective response rate (ORR) by iRECIST. Secondary EPs were disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and tolerability. Post-hoc analysis included tumor growth kinetics (TGK). Pts received E (30 mg SC Q2W for eight 3-week cycles and then Q3W up to 1 yr) with P (200 mg IV Q3W up to 2 yrs). Imaging was performed every 9 wks and locally evaluated. PD-L1 TPS was assessed using IHC 22C3 kit.

Results​

36 pts enrolled between Apr 2019 – Aug 2021. Median age was 67 yrs (46 – 84) and 61% were male. ECOG PS was 0 and 1 in 33% and 67% of pts. Pts had squamous (19%) and non-squamous (78%) histology. All PD-L1 subgroups were included: 39% with TPS <1% and 82% with TPS <50%. Pts received a PD-1/PD-L1 inhibitor alone (28%) or combined with platinum-based chemo (72%) as 1st line therapy. Pts received median of 5 (2 – 35) P and 7 (2 – 22) E doses.
ORR and DCR (iRECIST) was 8.3% and 33%. All PRs were confirmed with pts on study 19+ m. TGK analysis was performed on pts with data available on the same lesions from prior failed therapy and post-baseline. Vast majority (83%) of pts showed deceleration (50%) in tumor growth or shrinkage (33%) of target lesions. Median PFS was 2.1 months with PFS rate at 6 m of 25%. 44% were alive at 12 m with median OS of 9.7 m. Most common (>15%) adverse events were decreased appetite (33%), dyspnea (31%), cough (28%), asthenia (22%), fatigue (19%), arthralgia (17%) and weight decreased (17%).

Conclusions​

Efti + pembrolizumab is safe and shows encouraging signs of antitumor activity in NSCLC pts resistant to PD-1/PD-L1 inhibitors, warranting further investigation.

Clinical trial identification​

2018-001994-25 (EudraCT)
NCT03625323 (ClinicalTrials.gov)
 
Immutep's Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

Immutep announces new data evaluating efti in combination with pembrolizumab from Part B of the TACTI-002 Phase II trial in 2nd line PD-X refractory non-small cell lung cancer (NSCLC) patients has been accepted for a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023 taking place in Copenhagen, Denmark and virtually from 29 March to 1 April 2023.

Highlights
  • 2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting anti-PD-(L)1 therapy resistance
  • 83% of patients that were studied for Tumor Growth Kinetics showed deceleration (50%) in tumour growth or shrinkage (33%) of target lesions
  • Overall Response Rate (ORR) of 8.3% and Disease Control Rate (DCR) of 33% and responses were confirmed and durable with patients on study 19+ months
  • Important additional final data on safety and efficacy including Overall Survival (OS) from Part B of TACTI-002 will be presented in a Mini Oral presentation at ELCC 2023
  • 11MO - Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors (ID 420)​

    Speakers
    • Margarita Majem Tarruella (Barcelona, Spain)
    Duration
    5 Minutes

    Background​

    Eftilagimod alpha (E), a soluble LAG-3 protein, acts as an MHC class II agonist triggering activation of antigen-presenting cells (APC) and CD8 T-cells. Stimulating APCs and subsequent T cell recruitment with efti may revert PD-1/PD-L1 resistance. We report updated results from Part B of the TACTI-002 trial: 2nd line PD-1/PD-L1-resistant non-small cell lung carcinoma (NSCLC) patients (pts) treated with efti plus pembrolizumab (P).

    Methods​

    Pts with metastatic NSCLC unselected for PD-L1 expression and with resistance to 1st line PD-1/PD-L1 inhibitor-based therapy were enrolled. Primary endpoint (EP) was objective response rate (ORR) by iRECIST. Secondary EPs were disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and tolerability. Post-hoc analysis included tumor growth kinetics (TGK). Pts received E (30 mg SC Q2W for eight 3-week cycles and then Q3W up to 1 yr) with P (200 mg IV Q3W up to 2 yrs). Imaging was performed every 9 wks and locally evaluated. PD-L1 TPS was assessed using IHC 22C3 kit.

    Results​

    36 pts enrolled between Apr 2019 – Aug 2021. Median age was 67 yrs (46 – 84) and 61% were male. ECOG PS was 0 and 1 in 33% and 67% of pts. Pts had squamous (19%) and non-squamous (78%) histology. All PD-L1 subgroups were included: 39% with TPS <1% and 82% with TPS <50%. Pts received a PD-1/PD-L1 inhibitor alone (28%) or combined with platinum-based chemo (72%) as 1st line therapy. Pts received median of 5 (2 – 35) P and 7 (2 – 22) E doses.
    ORR and DCR (iRECIST) was 8.3% and 33%. All PRs were confirmed with pts on study 19+ m. TGK analysis was performed on pts with data available on the same lesions from prior failed therapy and post-baseline. Vast majority (83%) of pts showed deceleration (50%) in tumor growth or shrinkage (33%) of target lesions. Median PFS was 2.1 months with PFS rate at 6 m of 25%. 44% were alive at 12 m with median OS of 9.7 m. Most common (>15%) adverse events were decreased appetite (33%), dyspnea (31%), cough (28%), asthenia (22%), fatigue (19%), arthralgia (17%) and weight decreased (17%).

    Conclusions​

    Efti + pembrolizumab is safe and shows encouraging signs of antitumor activity in NSCLC pts resistant to PD-1/PD-L1 inhibitors, warranting further investigation.

    Clinical trial identification​

    2018-001994-25 (EudraCT)
    NCT03625323 (ClinicalTrials.gov)
    Immutep's Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023
  • Immutep announces new data evaluating efti in combination with pembrolizumab from Part B of the TACTI-002 Phase II trial in 2nd line PD-X refractory non-small cell lung cancer (NSCLC) patients has been accepted for a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023 taking place in Copenhagen, Denmark and virtually from 29 March to 1 April 2023.
Highlights
2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting anti-PD-(L)1 therapy resistance
83% of patients that were studied for Tumor Growth Kinetics showed deceleration (50%) in tumour growth or shrinkage (33%) of target lesions
Overall Response Rate (ORR) of 8.3% and Disease Control Rate (DCR) of 33% and responses were confirmed and durable with patients on study 19+ months
Important additional final data on safety and efficacy including Overall Survival (OS) from Part B of TACTI-002 will be presented in a Mini Oral presentation at ELCC 2023
 
Solo una "Mini Oral Presentation" per un'azienda che dovrebbe rivoluzionare il trattamento della cura ai tumori? Maaaa
 
Immutep's Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

Immutep announces new data evaluating efti in combination with pembrolizumab from Part B of the TACTI-002 Phase II trial in 2nd line PD-X refractory non-small cell lung cancer (NSCLC) patients has been accepted for a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023 taking place in Copenhagen, Denmark and virtually from 29 March to 1 April 2023.

Highlights
  • 2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting anti-PD-(L)1 therapy resistance
  • 83% of patients that were studied for Tumor Growth Kinetics showed deceleration (50%) in tumour growth or shrinkage (33%) of target lesions
  • Overall Response Rate (ORR) of 8.3% and Disease Control Rate (DCR) of 33% and responses were confirmed and durable with patients on study 19+ months
  • Important additional final data on safety and efficacy including Overall Survival (OS) from Part B of TACTI-002 will be presented in a Mini Oral presentation at ELCC 2023

  • Immutep's Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

  • Immutep announces new data evaluating efti in combination with pembrolizumab from Part B of the TACTI-002 Phase II trial in 2nd line PD-X refractory non-small cell lung cancer (NSCLC) patients has been accepted for a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023 taking place in Copenhagen, Denmark and virtually from 29 March to 1 April 2023.
Highlights
2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting anti-PD-(L)1 therapy resistance
83% of patients that were studied for Tumor Growth Kinetics showed deceleration (50%) in tumour growth or shrinkage (33%) of target lesions
Overall Response Rate (ORR) of 8.3% and Disease Control Rate (DCR) of 33% and responses were confirmed and durable with patients on study 19+ months
Important additional final data on safety and efficacy including Overall Survival (OS) from Part B of TACTI-002 will be presented in a Mini Oral presentation at ELCC 2023
mi sembrano risultati deludenti rispetto ai precedenti. È vero che non sono un oncologo e potrei aver detto una castroneria,ma i primi dati usciti indicavano 38 e 50%
sul market australiani volumi notevoli e praticamente invariato,-1,3%…mah
forse attendono i dati di fine mese per sentenziare.
 
Sempre sui pazienti 19+ mesi dici che prima era 38% e 50%?
 
Sempre sui pazienti 19+ mesi dici che prima era 38% e 50%?
ho notato solo questa differenza,ma non essendo medico ne avendone conoscenza potrei aver falsato l’interpretazione.
l’ho riportata confidando nell’intervento di qualcuno più ferrato
questa era la slide del 2020
https://www.immutep.com/files/content/investor/presentation/2020/ASCO 2020/TACTI-002 Poster ASCO2020_Final.pdf
mi scuso se ho creato scompiglio.
i volumi sono stati buoni,ma niente di straordinario,primo,indizio
la quotazione quasi invariata e’ un secondo indizio
io lo interpreto come una mossa anticipatoria,il problema pero‘ e’ la direzione:mmmm:
 
Ultima modifica:
Non trovo riferimento a quello che dici
 
Gracale per favore intervieni con un tuo commento. Grazie
 
bene Andrea,sempre chiaro. Ho preso un abbaglio. Ero un po’ preoccupato per le mie 7000 azioni già altine di pmc (2,4)
 
non so se qualcuno ha notato che ne sono passate di mano 1 milione in un colpo alle 13.36 orario di NY...
 
A prima vista sembrerebbe una vendita, il che è preoccupante
Screenshot_20230323_193917.jpg
 
Indietro